Previous close | 264.84 |
Open | 265.03 |
Bid | 265.20 x 900 |
Ask | 265.56 x 1000 |
Day's range | 263.18 - 265.94 |
52-week range | 182.09 - 265.94 |
Volume | |
Avg. volume | 2,571,603 |
Market cap | 196.875B |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | 48.77 |
EPS (TTM) | 5.45 |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | 1.08 (0.41%) |
Ex-dividend date | 28 Jun 2024 |
1y target est | 271.39 |
On May 16, 2024, Rainer Blair, President & CEO of Danaher Corp (NYSE:DHR), executed a sale of 9,005 shares of the company.
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.